Cencora, Inc. (NYSE:COR) COO Robert P. Mauch Sells 57,564 Shares

Cencora, Inc. (NYSE:COR) COO Robert P. Mauch sold 57,564 shares of Cencora stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the transaction, the chief operating officer now owns 24,412 shares of the company’s stock, valued at approximately $5,739,017.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cencora Stock Performance

Shares of Cencora stock opened at $238.60 on Thursday. The firm’s fifty day simple moving average is $237.53 and its 200-day simple moving average is $214.64. The stock has a market capitalization of $47.60 billion, a price-to-earnings ratio of 25.99, a PEG ratio of 1.79 and a beta of 0.45. Cencora, Inc. has a 12 month low of $163.37 and a 12 month high of $246.75. The company has a debt-to-equity ratio of 3.94, a current ratio of 0.88 and a quick ratio of 0.52.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, January 31st. The company reported $3.28 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.42. The business had revenue of $72.25 billion for the quarter, compared to analysts’ expectations of $68.81 billion. Cencora had a net margin of 0.69% and a return on equity of 323.23%. During the same period in the previous year, the company posted $2.71 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 13.43 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Friday, February 9th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.85%. This is a boost from Cencora’s previous quarterly dividend of $0.24. The ex-dividend date was Thursday, February 8th. Cencora’s payout ratio is presently 22.22%.

Hedge Funds Weigh In On Cencora

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. purchased a new position in Cencora in the 4th quarter valued at $4,212,508,000. State Street Corp boosted its position in shares of Cencora by 0.4% in the 1st quarter. State Street Corp now owns 7,419,026 shares of the company’s stock worth $1,187,860,000 after buying an additional 29,722 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Cencora by 2,004.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,171,292 shares of the company’s stock worth $691,225,000 after buying an additional 3,973,094 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cencora by 4.2% in the 1st quarter. Geode Capital Management LLC now owns 3,394,836 shares of the company’s stock worth $542,356,000 after buying an additional 138,287 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Cencora by 14.5% in the 4th quarter. Morgan Stanley now owns 2,565,873 shares of the company’s stock worth $425,191,000 after buying an additional 324,015 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. Barclays started coverage on shares of Cencora in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 price target for the company. Mizuho raised their price objective on shares of Cencora from $192.00 to $224.00 and gave the stock a “neutral” rating in a report on Monday, February 5th. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Finally, SVB Leerink started coverage on shares of Cencora in a report on Monday, February 26th. They set an “outperform” rating and a $261.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $218.22.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.